Valsartan/Hydrochlorothiazide: A review of its use in the management of hypertension

Keyphrases

• Hydrochlorothiazide 100%
• Hypertension Management 100%
• Valsartan 100%
• Amlodipine 30%
• Monotherapy 26%
• Tolerability 17%
• Antihypertensive Drugs 17%
• Blood Pressure Lowering 17%
• Moderate to Severe 13%
• Clinically Significant 8%
• Cardiac Function 8%
• Endothelial Function 8%
• Fixed-dose Combination 8%
• Double-blind Trial 8%
• Angiotensin Receptor Blockers 8%
• Patients with Hypertension 8%
• New-onset Diabetes Mellitus 8%
• 25Mg 8%
• Pharmacokinetics 4%
• Myocardial Infarction 4%
• Plasma Concentration 4%
• Potential Gains 4%
• Type 2 Diabetes Mellitus (T2DM) 4%
• Lisinopril 4%
• Inflammatory Biomarkers 4%
• Hyperglycemia 4%
• Atrial Fibrillation 4%
• Hypertension 4%
• Once-daily 4%
• Headache 4%
• Cardiovascular Outcomes 4%
• Blood Pressure 4%
• Kidney 4%
• Heart Rate 4%
• Aging Effect 4%
• Pharmacokinetic Effects 4%
• Older Patients 4%
• High Cardiovascular Risk 4%
• Syncope 4%
• Renal Disease 4%
• Therapeutic Efficacy 4%
• Elderly Patients 4%
• Efficacy Profile 4%
• Dizziness 4%
• Non-inferiority 4%
• Dyslipidemia 4%
• Reactive Oxygen Species 4%
• Adverse Events 4%
• Cardiac Output 4%
• Systolic Blood Pressure 4%
• Diastolic Blood Pressure 4%
• Mean Arterial Pressure 4%
• Plasma Volume 4%
• Drug Combination 4%
• Essential Hypertension 4%
• Stroke Volume 4%
• Elimination Half-life 4%
• Isolated Systolic Hypertension 4%
• Cardiac Mortality 4%
• Hepatic Dysfunction 4%
• Left Ventricular Mass 4%
• African American Patients 4%
• Hypokalemia 4%
• Selective Antagonist 4%
• Angina Pectoris 4%
• Serious Adverse Events 4%
• Angiotensin II Type 1 Receptor (AT1R) 4%
• Orthostatic Hypotension 4%
• Peak Concentration 4%
• Lipid Profile 4%
• C-reactive Protein Level 4%
• Black African 4%
• Pharmacological Properties 4%
• Total Peripheral Resistance 4%
• Severe Hypertension 4%
• Therapy Regimen 4%
• Cardiac Morbidity 4%
• Equivalent Reduction 4%
• Cl Transport 4%
• Systemic Clearance 4%
• Thiazide Diuretics 4%
• Diuretic Drugs 4%
• Basal Nitric Oxide 4%
• Angioneurotic Edema 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Hydrochlorothiazide 100%
• Hydrochlorothiazide Plus Valsartan 100%
• Valsartan 92%
• Amlodipine 53%
• Monotherapy 46%
• Tolerability 30%
• Antihypertensive Agent 30%
• Angiotensin Receptor Antagonist 15%
• Adverse Event 15%
• Diabetes Mellitus 15%
• Pharmacokinetics 15%
• Elimination 7%
• Heart Infarction 7%
• Biological Marker 7%
• Cerebrovascular Accident 7%
• Receptor 7%
• Headache 7%
• Hydrochlorothiazide Plus Lisinopril 7%
• Cardiovascular Risk 7%
• Liver Dysfunction 7%
• Faintness 7%
• Diuretic Agent 7%
• Angiotensin II 7%
• Essential Hypertension 7%
• C Reactive Protein 7%
• Reactive Oxygen Metabolite 7%
• Dizziness 7%
• Thiazide Diuretic Agent 7%
• Orthostatic Hypotension 7%
• Angina Pectoris 7%
• Systolic Hypertension 7%
• Hypokalemia 7%
• Angioneurotic Edema 7%
• Combination Drug 7%
• Dyslipidemia 7%
• Combination Therapy 7%
• Atrial Fibrillation 7%
• Nitric Oxide 7%
• Hyperglycemia 7%
• Non Insulin Dependent Diabetes Mellitus 7%